MRM’s platform could optimise the link between the gut microbiome and cancer outcomes
News
Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
Arthrosi’s investigational gout treatment is currently being evaluated in global studies
Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
The two companies aim to reduce administrative burden and speed up drug delivery
Title21 Health Solutions joins the Blood and Cells Advocacy Roster
The blood industry plays a vital role in supporting the development of advanced therapies
NADMED launches $30,000 metabolomics research award
Winners will receive metabolomics kits, expert consultation and measurement services
eXmoor Pharma and UCL establish strategic cell and gene therapy collaboration
Cell and gene therapies are often delayed by technical and regulatory issues
Miranda Dini launches GOLD amid industry shifts
New consultancy aims to deliver personalised senior expertise in healthcare communications
Genfit reports promising phase 1b data in cholangiocarcinoma
Results show disease control and tumour shrinkage with GNS561 and MEK inhibitor combination
GRI Bio reports positive phase 2a data in idiopathic pulmonary fibrosis
Trial shows GRI-0621 improved lung function with signs of fibrosis resolution
Immunotherapy combination shows unprecedented results in multiple myeloma
MajesTEC-3 study supports teclistamab plus daratumumab SC as potential standard of care
Modus Therapeutics advances sevuparin study in chronic kidney disease with anemia
Proof-of-concept phase begins with first patient enrolled
Five-year study confirms durable efficacy of etranacogene dezaparvovec
Gene therapy shows sustained benefit for adults with haemophilia B
Enterprise Therapeutics publishes results of phase 1 study of ETD001
Novel inhaled ENaC blocker shows promise for treatment of cystic fibrosis
Rybrevant accepted in Scotland for lung cancer treatment
SMC approves targeted therapy for patients with EGFR exon 20 insertion mutations
Early use of CARVYKTI shows lasting remissions in multiple myeloma
Johnson & Johnson reports phase 3 data highlighting durable outcomes and immune fitness benefits
